Navigation Links
Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
Date:12/15/2016

PLEASANTON, Calif., Dec. 15, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has officially notified Pacific Bioscience (PacBio) of its intention to terminate its agreement and efforts to develop a sequencing instrument for use in the clinical research and clinical market using their Single Molecule, Real-Time (SMRT®) technology.

With this termination, Roche no longer retains rights to this technology and PacBio is free to approach any market segments with their SMRT technology.

"As a result of this decision we will have greater focus on our internal development efforts and drive our long term strategy which is to be a leader in clinical diagnostic sequencing," said Neil Gunn, Head of Roche Sequencing Solutions.  "We are continuing to actively pursue multiple technologies and commercial strategies internally and externally to ensure we address the specific needs of our customers in the clinical diagnostic sequencing market segment."

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. *All trademarks used or mentioned in this release are protected by law. 

For further information, please contact:

Roche Sequencing Solutions
Elizabeth Baxter
Corporate Communications
Mobile: 925.523.8812
elizabeth.baxter@roche.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roche-announces-termination-of-2013-development-commercialization-and-license-agreement-with-pacific-biosciences-300379155.html


'/>"/>
SOURCE Roche
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Atomic Force Microscope Leader Park Systems Presents Webinar on Electrochemical Scanned Probes June 16, 2016
2. Say it with Pictures: SPIE Donates Photonics Infographics Books to Rochester Science Museum
3. Roche launches new chromogen for cancer research
4. OHAUS Corporation Unveils New Laboratory Balances and Electrochemistry Meters At Pittcon 2016
5. Atomic Force Microscope Leader Park Systems Presents Electrochemistry Webinar
6. BD Boston Conference Hosted by BD Heads of Shire, Merck, Sanofi, Roche, Biogen, Teva, Nestle, AbbVie on March 9th
7. Cellular Dynamics Announces Collaboration with Roche
8. Global Biologic Therapeutics Market 2015-2019 Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk & Sanofi
9. Genetic Testing Market Outlook 2015-2020: Key Vendors Influencing the Industry Include Abbott, Roche, Siemens, Illumina, Thermo Fischer Scientific, and Myriad Genetics
10. Roche strengthens oncology translational research pipeline by acquiring CAPP Medical
11. Global HER-2 Positive Breast Cancer Market 2015-2019 - Key Players are Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... line of medical marijuana products targeting the needs of consumers who are incorporating ... Kindred takes place in Phoenix, Arizona. , As operators of two successful Valley ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
(Date:10/6/2017)... ... October 06, 2017 , ... On ... and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The ... The event is free and open to the public, but registration is required. ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):